Tamara Crockett, Esq
President and Chief Executive Officer
Tamara has more than 25 years' experience in leading, managing and advising technology companies on all aspects of technology development and commercialization. Tamara is an intellectual property attorney with expertise in all aspects of patent portfolio management. She has held numerous positions in private law firms, government and private companies. She is a member of the bar in New York, Massachusetts, Arizona and the District of Columbia.
Meredith Hay, Ph.D
Founder and Chief Science Officer
Dr. Hay is the visionary and one of the inventors of the founding technology. She has over 25 years of experience in neuroscience and cardiovascular neurophysiology. She is the former Executive Vice President and Chief Operating Officer for the University of Arizona for former Vice President for Research, University of Iowa. She currently is a tenured professor at the University of Arizona College of Medicine. Dr. Hay has generated over $10 M in external R&D funding and nearly 20 NIH and related grants.
Rodney Lax, Ph.D.
Peptide Chemistry Development
Has over 35 years of experience in peptide chemistry, manufacturing and therapeutic development. In 1997, he joined WHERL GmbH (which in 1998 became PolyPeptide Laboratories GmbH) as Director of Sales & Marketing. In February 2003 he moved to the PolyPeptide Laboratories, Inc. in California as Senior Director of Business Development. He received his lectureship (Habilitation) in Physiological Chemistry in 1978 and became an Associate Professor at the University of Essen in 1985. After leaving academia in 1986, he then worked for a number of small biotech companies involved in peptide-based pharmaceuticals in Northern Germany, including Bissendorf Peptides GmbH, Pharma Biotechnology Hannover GmbH and Saxon Biochemicals.
Bruce Coull, M.D.
Chief Medical Officer
Dr. Coull is internationally known for his expertise in stroke, vascular neurology and brain inflammation and has over 35 years of experience in neurology and clinical trial management. He is a professor of Neurology and Medicine, Vice dean for clinical affairs at the University of Arizona College of Medicine – Tucson and served as Chief Medical Officer for The University of Arizona Physicians. Dr. Coull is author and co-author of over 130 peer-reviewed journals, book chapters and other publications. He is an expert in human vascular neurology and has been voted one of the "Best Doctors in America" 2008, 2009, 2010, 2011, 2013, 2014.
Director of Regulatory Affairs and Manufacturing
Peter has 30+ years' experience in leading CMC and regulatory activities in the biomedical industry. Peter has held various positions, including Chief Regulatory Officer, Chief Operations Officer, Vice President of CMC and Head of Operations for several US-based companies. Peter started his career at Genentech, where he held several technical and leadership positions in pharmaceutical development and manufacturing and drug delivery.
Kathy Rodgers, Ph.D.
Director of Toxicology
Kathy is an expert in pharmacology and toxicology with extensive experience in angiotensin peptides and small molecule Mas agonists. Her research interests include cardiovascular pharmacology, neuroscience and toxicology. Kathy is the author of several hundred research articles and inventor on numerous patents. She is certified by the American Board of Toxicology. Currently, she serves as Associate Director Translational Neuroscience and Professor of Pharmacology at the University of Arizona.
Holly Sparkman, CPA, CVA
Chief Financial Officer
Holly specializes in tax, valuation and CFO consulting services. She has experience overseeing company growth, including start-up and venture capital backed entities, through private sales and IPOs. She serves as principal at Rorie, Sparkman and Engel. Previously, she was with KPMG Peat Marwick.